Article information
Full text is only aviable in PDF
Bibliografía
[1.]
ASCPT (American Society for Clinical Pharmacology and Therapeutics).
Pharmacoepidemiology Section. Position paper on the use of purported postmarketing surveillance studies for promotional purposes.
Clin Pharmacol Ther, 40 (1990), pp. 598
[2.]
Stephens MDB.
Marketing aspects of company-sponsored postmarketing surveillance studies.
Drug Safety, 8 (1993), pp. 1-8
[3.]
M. Porta-Serra.
Los ensayos clínicos de fase IV: ¿por qué, cúando y cómo?.
Metodología del Ensayo Clínico, pp. 31-33
[4.]
DGFPS Circular nº 18/90. Directrices para la realización de estudios de farmacovigilancia
[5.]
S.E. Schonberg.
Relations between physicians and pharmaceutical companies: where to draw the line.
N Engl J Med, 323 (1990), pp. 200
[6.]
M.A. Jenike.
Relations between physicians and pharmaceutical companies: where to draw the line.
N Engl J Med, 323 (1990), pp. 201
[7.]
T.A. Sheldon, G.D. Smith.
Consensus conferences as drug promotion.
Lancet, 341 (1993), pp. 100-102
[8.]
J.F. Olalla, J.J. Gérvas.
Relaciones entre la industria farmacéutica y los profesionales sanitarios.
Gac Sanit, 3 (1989), pp. 389-391
[9.]
F. Felices.
Una propuesta de decálogo deontológico.
Med Clín (Barc), 98 (1992), pp. 799-800
[10.]
Anonimo.
Where to draw the line.
Lancet, ii (1986), pp. 849
[11.]
S. Garattini.
Italy: and end to the fun and games?.
Lancet, 338 (1991), pp. 749-750
[12.]
T. Keates.
Tug-of-war over italian pharmaceutical prices.
Lance/, 344 (1994), pp. 321-322
Copyright © 1995. Sociedad Española de Salud Pública y Administración Sanitaria
